Loxagen is developing the first oral, cost competitive therapy for Type 1 Diabetes, with an experienced developmental team that has taken multiple drugs to the clinic and world class clinicians.
Open Culture Science automates cell and tissue culture with compact, programmable microfluidic platforms and cloud connected workflows for reproducible, high-fidelity research and non-animal preclinical testing.
UC Agricultural and Natural Resources
Spectral Analytix develops solutions based on imaging data for the classification and sorting of seeds as part of selection of elite breeding materials and reforestation efforts.
Yeast Bay Bio is developing a platform for species-specific pest control using innovative yeast technology. Our products eliminate pests from your home without the risk to people, pets, or the surrounding ecosystem.
UC Davis
illumifyDx is developing a blood-based optical diagnostic platform that measures the body’s molecular state in a single, unified test. Starting with head and neck cancer, our platform scales across diseases and care settings.
Pet Allies is an expert-led, AI-enabled behavioral care platform built with UC Davis veterinary expertise, distributed in partnership with clinics and shelters to scale subscription-based support for millions of pet families.
UC Riverside
TollRAir is a biotherapeutic company developing TollairaTM, a first-in-class patent-pending combination biotherapy to target Non-Allergic Steroid-Resistant Endotoxin-Induced Asthma (NASREA), with demonstrated preclinical efficacy and superior formulation stability.
Water Illumination develops patented vacuum-UV water treatment systems that destroy PFAS (Per- and Polyfluoroalkyl Substances) and other emerging contaminants inline achieving non-detect performance under ambient conditions with no toxic waste.
UC Los Angeles
NEXT TFX is developing ultra-high-pressure reverse osmosis membranes that reduce energy use for desalination and brine concentration, unlocking water reuse and critical mineral recovery at an industrial scale.
Desna Therapeutics is pioneering precision immune reprograming to treat type 1 diabetes and other autoimmune diseases. Our disruptive platform uses a clinically proven mechanism to specifically ‘turn off’ autoimmune diseases
UC Berkeley
Archer Therapeutics is a community funded biotech, dedicated to making affordable genetic medicines for cancer patients. Our potent nucleic acid technology enhances anti-cancer responses, increasing cancer survival from 20 to 80% in model system.
Elenae Therapeutics is building a precision RNA medicine platform combining an AI-guided ASO design engine with broadly tissue-distributed LNA mixmers, advancing heart failure and dry age-related macular degeneration programs and pursuing strategic Pharma partnerships.
UC Irvine
SoundDose is developing radiacoustic dosimetry, technology that will significantly improve on-target cancer treatment. Developed at UCI’s TRUE Lab, the tech has received $12m in NIH funding and is entering human trials Q1-2026.
NeuroQure has launched the world’s first biophysical test for autism risk at birth, unlocking objective biological insight within days of life, activating earlier intervention, and transforming a child’s lifelong developmental trajectory.
UC San Diego
GelTech Labs is building the automated testing infrastructure accelerating hydrogel breakthroughs in medicine, hygiene, and sustainable materials.
Katomed Serial MedTech founder-operators behind two FDA firsts, now building the infrastructure to make surgical precision measurable, repeatable, and scalable
UC San Francisco
MateBio turns black-box AI and disconnected biomedical data into a unified, hallucination-free knowledge engine— delivering traceable, groundbreaking insights for faster R&D. Trusted by top organizations including FormationBio, Pfizer, and NASA.
Hydronovo is developing a regenerative hydrogel therapy restoring salivary gland function in xerostomia. Backed by $9M non-dilutive funding, GLP safety data, and UCSF licensing, we are advancing toward first-in-human trials.
